These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31442904)

  • 1. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
    Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
    Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
    Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
    Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
    Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
    Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
    Rolla S; Maglione A; De Mercanti SF; Clerico M
    Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
    Baker D; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
    Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
    Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID.
    Fiorella C; Lorna G
    Mult Scler Relat Disord; 2020 Nov; 46():102447. PubMed ID: 32835901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
    Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
    Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
    Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab.
    Eichau S; López Ruiz R; Castón Osorio JJ; Ramírez E; Domínguez-Mayoral A; Izquierdo G
    Neurologia (Engl Ed); 2020; 35(6):440-443. PubMed ID: 29907474
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab for Multiple Sclerosis.
    Willis MD; Robertson NP
    Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
    Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
    Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
    Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
    Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
    [No Abstract]   [Full Text] [Related]  

  • 16. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
    Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
    JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
    Graf J; Ringelstein M; Lepka K; Schaller J; Quack H; Hartung HP; Aktas O; Albrecht P
    Mult Scler; 2018 Nov; 24(13):1776-1778. PubMed ID: 30307371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
    Khachanova NV; Bakhtiyarova KZ; Boyko AN; Vlasov YV; Davydovskaya MV; Evdoshenko EP; Zakharova MN; Kotov SV; Popova EV; Sivertseva SA; Totolyan NA; Khabirov FA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3):82-91. PubMed ID: 32323949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
    Adamec I; Habek M
    Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.